{"title":"Brain metastases in newly diagnosed lung cancer: epidemiology and conditional survival.","authors":"Chong Yuan, Huandong Zheng","doi":"10.21037/tcr-24-776","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The brain serves as the primary site for metastasis in patients with both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The presence of lung cancer with brain metastasis (LCBM) is a debilitating condition associated with considerable morbidity and mortality. The objective of this study was to assess the incidence and survival rates of LCBM in the United States population.</p><p><strong>Methods: </strong>We analyzed a total of 9,212 patients diagnosed with LCBM between 2010 and 2015, extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Our analysis assessed the incidence, relative survival, and conditional survival (CS) of LCBM. We utilized the Kaplan-Meier method to estimate overall survival and determine CS at year y+x after x years of survival, following the formula CS(y|x) = CS(y+x)/CS(x). Prognostic factor selection was performed using the least absolute shrinkage and selection operator (LASSO) regression approach, and multivariate Cox regression was employed to demonstrate the impact of these predictors on outcomes and construct a CS-based nomogram.</p><p><strong>Results: </strong>The overall age-adjusted incidence rate of LCBM was 5.82 cases per 100,000, with a slight decline observed during our study period. Patient relative survival showed a continuous decline with increasing age. CS analysis revealed that the 5-year CS rate for patients initially diagnosed with LCBM adjusted from 3% to 13%, 28%, 52%, and 73% over successive years of survival (1-4 years). Identified predictors included age at diagnosis, sex, race, tumor size, tumor grade, surgery, radiotherapy, and chemotherapy. These predictors, along with the CS formula, were employed to develop a CS-based nomogram for real-time prognosis prediction. Calibration curve, area under the time-dependent receiver operating characteristic (ROC) curve, concordance index (c-index), and decision curve analysis (DCA) demonstrated the model's strong predictive capabilities.</p><p><strong>Conclusions: </strong>This study deepened our understanding of LCBM patients, summarizing their epidemiological characteristics and CS patterns. We successfully developed a novel CS-based nomogram model for dynamic survival estimation, offering real-time and personalized prognostic information that is clinically valuable.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"13 10","pages":"5417-5428"},"PeriodicalIF":1.5000,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11543091/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tcr-24-776","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/25 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The brain serves as the primary site for metastasis in patients with both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The presence of lung cancer with brain metastasis (LCBM) is a debilitating condition associated with considerable morbidity and mortality. The objective of this study was to assess the incidence and survival rates of LCBM in the United States population.
Methods: We analyzed a total of 9,212 patients diagnosed with LCBM between 2010 and 2015, extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Our analysis assessed the incidence, relative survival, and conditional survival (CS) of LCBM. We utilized the Kaplan-Meier method to estimate overall survival and determine CS at year y+x after x years of survival, following the formula CS(y|x) = CS(y+x)/CS(x). Prognostic factor selection was performed using the least absolute shrinkage and selection operator (LASSO) regression approach, and multivariate Cox regression was employed to demonstrate the impact of these predictors on outcomes and construct a CS-based nomogram.
Results: The overall age-adjusted incidence rate of LCBM was 5.82 cases per 100,000, with a slight decline observed during our study period. Patient relative survival showed a continuous decline with increasing age. CS analysis revealed that the 5-year CS rate for patients initially diagnosed with LCBM adjusted from 3% to 13%, 28%, 52%, and 73% over successive years of survival (1-4 years). Identified predictors included age at diagnosis, sex, race, tumor size, tumor grade, surgery, radiotherapy, and chemotherapy. These predictors, along with the CS formula, were employed to develop a CS-based nomogram for real-time prognosis prediction. Calibration curve, area under the time-dependent receiver operating characteristic (ROC) curve, concordance index (c-index), and decision curve analysis (DCA) demonstrated the model's strong predictive capabilities.
Conclusions: This study deepened our understanding of LCBM patients, summarizing their epidemiological characteristics and CS patterns. We successfully developed a novel CS-based nomogram model for dynamic survival estimation, offering real-time and personalized prognostic information that is clinically valuable.
期刊介绍:
Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients'' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.